These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21984826)

  • 1. Epstein-Barr viral BNLF2a protein hijacks the tail-anchored protein insertion machinery to block antigen processing by the transport complex TAP.
    Wycisk AI; Lin J; Loch S; Hobohm K; Funke J; Wieneke R; Koch J; Skach WR; Mayerhofer PU; Tampé R
    J Biol Chem; 2011 Dec; 286(48):41402-41412. PubMed ID: 21984826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.
    Horst D; Favaloro V; Vilardi F; van Leeuwen HC; Garstka MA; Hislop AD; Rabu C; Kremmer E; Rickinson AB; High S; Dobberstein B; Ressing ME; Wiertz EJ
    J Immunol; 2011 Mar; 186(6):3594-605. PubMed ID: 21296983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.
    Horst D; van Leeuwen D; Croft NP; Garstka MA; Hislop AD; Kremmer E; Rickinson AB; Wiertz EJ; Ressing ME
    J Immunol; 2009 Feb; 182(4):2313-24. PubMed ID: 19201886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.
    Strong MJ; Laskow T; Nakhoul H; Blanchard E; Liu Y; Wang X; Baddoo M; Lin Z; Yin Q; Flemington EK
    J Virol; 2015 Oct; 89(19):10110-4. PubMed ID: 26178981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
    Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
    PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
    Jochum S; Moosmann A; Lang S; Hammerschmidt W; Zeidler R
    PLoS Pathog; 2012; 8(5):e1002704. PubMed ID: 22615564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
    Khanna R; Burrows SR; Moss DJ; Silins SL
    J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.
    Horst D; Burrows SR; Gatherer D; van Wilgenburg B; Bell MJ; Boer IG; Ressing ME; Wiertz EJ
    J Virol; 2012 Jan; 86(1):572-7. PubMed ID: 22013037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.
    Lee SP; Thomas WA; Blake NW; Rickinson AB
    Eur J Immunol; 1996 Aug; 26(8):1875-83. PubMed ID: 8765034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.
    Ressing ME; Keating SE; van Leeuwen D; Koppers-Lalic D; Pappworth IY; Wiertz EJ; Rowe M
    J Immunol; 2005 Jun; 174(11):6829-38. PubMed ID: 15905524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAP-independent antigen presentation on MHC class I molecules: lessons from Epstein-Barr virus.
    Lautscham G; Rickinson A; Blake N
    Microbes Infect; 2003 Apr; 5(4):291-9. PubMed ID: 12706442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
    Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
    Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
    J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses.
    Verweij MC; Ressing ME; Knetsch W; Quinten E; Halenius A; van Bel N; Hengel H; Drijfhout JW; van Hall T; Wiertz EJ
    Mol Immunol; 2011 Mar; 48(6-7):835-45. PubMed ID: 21292324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10.
    Zeidler R; Eissner G; Meissner P; Uebel S; Tampé R; Lazis S; Hammerschmidt W
    Blood; 1997 Sep; 90(6):2390-7. PubMed ID: 9310490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An annular lipid belt is essential for allosteric coupling and viral inhibition of the antigen translocation complex TAP (transporter associated with antigen processing).
    Eggensperger S; Fisette O; Parcej D; Schäfer LV; Tampé R
    J Biol Chem; 2014 Nov; 289(48):33098-108. PubMed ID: 25305015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence analysis of EBV immune evasion gene BNLF2a in EBV associated tumors and healthy individuals from nasopharyngeal carcinoma endemic and non-endemic regions of China.
    Liu S; Wang X; Shu J; Zhao Z; Sun Z; Luo B
    J Med Virol; 2015 Nov; 87(11):1946-52. PubMed ID: 25959517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of activation of the BNLF2a immune evasion gene of Epstein-Barr virus by Zta.
    Almohammed R; Osborn K; Ramasubramanyan S; Perez-Fernandez IBN; Godfrey A; Mancini EJ; Sinclair AJ
    J Gen Virol; 2018 Jun; 99(6):805-817. PubMed ID: 29580369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.
    Frisan T; Zhang QJ; Levitskaya J; Coram M; Kurilla MG; Masucci MG
    Int J Cancer; 1996 Oct; 68(2):251-8. PubMed ID: 8900437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.